A Phase 3 interventional study of 18F fluciclovine in Brain Metastases, sponsored by Blue Earth Diagnostics. Completed at 19 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-28.
Sponsored by Blue Earth Diagnostics (part of Bracco) · Phase 3, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,443 studies in Brain Neoplasms with a site in United States — 229 open to participants now, 352 under way, 18 of them phase 3. Brain Neoplasms · United States.
Among the 1,443 studies in Brain Neoplasms with a site in United States, this one is the 105th largest by enrollment of the 1,188 interventional ones that give a count, is one of 43 that started in 2020, is one of 70 in phase 3, and was the 1,117th registered.
2,441 studies on the registry are indexed under Brain Neoplasms; 541 are open to participants now.
Browse Brain Neoplasms studies →229 of the 1,443 studies in Brain Neoplasms with a site in United States are open now. Recruiting first, the newest first:
Brian J.Gill · Sites in United States
Ages 22–65
Stanford University · Sites in United States
Ages 6 mo–25 yrs
University of California, San Francisco · Sites in United States
Ages 18+
Beijing Inno Medicine Co., Ltd. · Sites in United States, China
Ages 18–70
University of Florida · Sites in United States
Ages 18–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 425 Brain Neoplasms studies recruiting now, 286 (67%) set no upper age limit and 82 (19%) stop at 75 or younger; 80 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,443 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 552 · Phase 2 520 · Phase 3 72 · Phase 4 18
First in 1979; this study’s year is marked. 43 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 151 is above the median of 40 across 1,832 interventional studies indexed under Brain Neoplasms.
Median enrollment 30 across the 1,188 interventional studies, 76 across the 191 observational. Of the 993 that completed or were terminated, 355 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
221 of 1,443 have an industry lead sponsor. The 10 most frequent:
This study is registered under Blue Earth Diagnostics, one of the names counted as Bracco. Under that name alone:
Blue Earth Diagnostics is the lead sponsor of 12 studies on the registry; 3 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 5 (100%) have results posted.
Bracco has 3 studies filed under Brain Neoplasms — fewer than ten, so there is no comparison to draw.
141 of the studies in Brain Neoplasms with a site in United States that are under way reach primary completion within a year, 8 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT00978458Phase 3Eastern Cooperative Oncology GroupRadiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma | 2026-12-31 |
| NCT03741673Phase 3M.D. Anderson Cancer CenterPre-operative SRS or Post-operative SRS in Treating Cancer Patients With Brain Metastases | 2027-01-31 |
| NCT05438212Phase 3NRG OncologyComparing the Addition of Radiation Either Before or After Surgery for Patients With Brain Metastases | 2027-03-16 |
| NCT05271240Phase 3Northwell HealthRepeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM | 2027-04-01 |
| NCT00950001Phase 3M.D. Anderson Cancer CenterStereotactic Radiosurgery Compared to Observation in Treating Patients With Brain Metastases | 2027-04-30 |
Add all 141 to your calendar (.ics) → With an account.
Among the 1,443 studies in Brain Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
An open-label, single dose, single arm, prospective, multicenter Phase 3 study to establish the diagnostic performance of 18F fluciclovine positron emission tomography (PET) in detecting recurrent brain metastases after radiation therapy
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
1. Patients with a history of active hematological
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single intravenous administration of 18F fluciclovine for PET Scan
Drug: 18F fluciclovine
18F fluciclovine injection, 185 MBq (5 mCi) ± 20%, delivered as an intravenous bolus
Also known as: Axumin
Positive Percent Agreement (PPA) and Negative Percent Agreement (NPA) Subject Level
Subject-level PPA and NPA (equivalent to sensitivity and specificity, respectively) of 18F-fluciclovinePET in detecting recurrent brain metastases.
Time frame: MRI for anatomical correlation within 3 days of IMP and PET scan, followed by surgical intervention (if applicable) post-PET scan and follow up through 6 months after PET scan.
Subject Level Positive Predictive Value (PPV) and Negative Predictive Value (NPV)
Subject-level PPV and NPV of 18F-fluciclovine PET for detecting recurrent brain metastases
Time frame: MRI for anatomical correlation within 3 days of IMP and PET scan, followed by surgical intervention (if applicable) post-PET scan and follow up through 6 months after PET scan.
Lesion-level Positive Percent Agreement (PPA) and Negative Percent Agreement (NPA)
To assess lesion-level PPA \& NPA diagnostic performance of 18F-fluciclovine PET in detecting recurrent brain metastases.
Time frame: MRI for anatomical correlation within 3 days of IMP and PET scan, followed by surgical intervention (if applicable) post-PET scan and follow up through 6 months after PET scan.
Lesion-level Positive Predictive Value (PPV) and Negative Predictive Value (NPV)
To assess lesion-level PPV \& NPV diagnostic performance of 18F-fluciclovine PET in detecting recurrent brain metastases.
Time frame: MRI for anatomical correlation within 3 days of IMP and PET scan, followed by surgical intervention (if applicable) post-PET scan and follow up through 6 months after PET scan.
Subject-level Positive Percent Agreement (PPA) & Negative Percent Agreement (NPA) Diagnostic Performance of Fluciclovine (18F) PET in Detecting Recurrent Brain Metastases in Different Clinical Settings - Tumor Type
Sub-group analyses of subject-level PPA \& NPA of fluciclovine (18F) PET, according to primary tumor type.
Time frame: MRI for anatomical correlation within 3 days of IMP and PET scan, followed by surgical intervention (if applicable) post-PET scan and follow up through 6 months after PET scan.
Subject-level Positive Predictive Value (PPV) & Negative Predictive Value (NPV) Diagnostic Performance of Fluciclovine (18F) PET in Detecting Recurrent Brain Metastases in Different Clinical Settings - Tumor Type
Sub-group analyses of subject-level PPV \& NPV of fluciclovine (18F) PET, according to primary tumor type.
Time frame: MRI for anatomical correlation within 3 days of IMP and PET scan, followed by surgical intervention (if applicable) post-PET scan and follow up through 6 months after PET scan.
Subject-level Positive Percent Agreement (NPA) & Negative Percent Agreement (NPA) Diagnostic Performance of Fluciclovine (18F) PET in Detecting Recurrent Brain Metastases in Different Clinical Settings - Concurrent Immunotherapy
Sub-group analyses of subject-level PPA \& NPA of fluciclovine (18F) PET, according to concurrent immunotherapy.
Time frame: MRI for anatomical correlation within 3 days of IMP and PET scan, followed by surgical intervention (if applicable) post-PET scan and follow up through 6 months after PET scan.
Subject-level Positive Predictive Value (PPV) & Negative Predictive Value (NPV) Diagnostic Performance of Fluciclovine (18F) PET in Detecting Recurrent Brain Metastases in Different Clinical Settings - Concurrent Immunotherapy
Sub-group analyses of subject-level PPV \& NPV of fluciclovine (18F) PET, according to Concurrent Immunotherapy.
Time frame: MRI for anatomical correlation within 3 days of IMP and PET scan, followed by surgical intervention (if applicable) post-PET scan and follow up through 6 months after PET scan.
Clinical Usefulness
Number of days taken by the site to establish presence/absence of metastasis by clinical follow-up.
Time frame: Follow up through 6 months after PET scan.
Clinical Usefulness
Proportion of subjects with additional metastases identified on fluciclovine (18F) PET in addition to SoC brain MRI
Time frame: Follow up through 6 months after PET scan.
Clinical Usefulness
Proportion of subjects whose prospective diagnostic management plan changed following fluciclovine (18F) PET.
Time frame: Follow up through 6 months after PET scan.
Inter-reader Reproducibility
Pairwise comparisons of the central reads for the 3 readers (i.e. Reader 1 vs Reader 2, Reader 1 vs Reader 3, and Reader 2 vs Reader 3) at the subject-level. The percentage of results in agreement (i.e. Positive \[1st reader\] / Positive \[2nd reader\], Negative/Negative) is presented.
Time frame: PET Scan Day 1
Intra-reader Reproducibility
Pairwise comparisons of the initial read vs re-read of a subset of PET scans for each reader at the subject-level. The percentage of results in agreement (i.e. Positive \[initial read\] / Positive \[re-read\], Negative/Negative) is presented.
Time frame: PET Scan Day 1
Assess the Safety of Fluciclovine (18F) Injection in the Subject Population, Blood Pressure
Treatment-emergent adverse events (TEAEs) following 18F-fluciclovine injection in the subject population.
Time frame: The vital signs collected between 5 to 60 minutes before and after the PET scan.
Assess the Safety of Fluciclovine (18F) Injection in the Subject Population, Heart Rate
Treatment-emergent adverse events (TEAEs) following 18F-fluciclovine injection in the subject population.
Time frame: The vital signs collected between 5 to 60 minutes before and after the PET scan.
Assess the Safety of Fluciclovine (18F) Injection in the Subject Population, Respiratory Rate
Treatment-emergent adverse events (TEAEs) following 18F-fluciclovine injection in the subject population.
Time frame: The vital signs collected between 5 to 60 minutes before and after the PET scan.
Assess the Safety of Fluciclovine (18F) Injection in the Subject Population, Body Temperature
Treatment-emergent adverse events (TEAEs) following 18F-fluciclovine injection in the subject population.
Time frame: The vital signs collected between 5 to 60 minutes before and after the PET scan.
| Milestone | Subjects Receiving Single IV Administration of 18F Fluciclovine for PET Scan |
|---|---|
| Started | 151 |
| Completed | 151 |
| Not completed | 0 |
Subject-level PPA and NPA (equivalent to sensitivity and specificity, respectively) of 18F-fluciclovinePET in detecting recurrent brain metastases.
| percentage | Reader 1 - Positive Percent Agreement (PPA) | Reader 2 - Positive Percent Agreement (PPA) | Reader 3 - Positive Percent Agreement (PPA) | Reader 1 - Negative Percent Agreement (NPA) | Reader 2 - Negative Percent Agreement (NPA) | Reader 3 - Negative Percent Agreement (NPA) |
|---|---|---|---|---|---|---|
| Positive Percent Agreement (PPA) and Negative Percent Agreement (NPA) Subject Level | 23.8 (12.1 to 39.5) | 34.1 (20.1 to 50.6) | 36.6 (22.1 to 53.1) | 82.6 (74.1 to 89.2) | 70.9 (61.5 to 79.2) | 70.9 (61.5 to 79.2) |
Subject-level PPV and NPV of 18F-fluciclovine PET for detecting recurrent brain metastases
| percentage | Reader 1 - Positive Predictive Value (PPV) | Reader 2 - Positive Predictive Value (PPV) | Reader 3 - Positive Predictive Value (PPV) | Reader 1 - Negative Predictive Value (NPV) | Reader 2 - Negative Predictive Value (NPV) | Reader 3 - Negative Predictive Value (NPV) |
|---|---|---|---|---|---|---|
| Subject Level Positive Predictive Value (PPV) and Negative Predictive Value (NPV) | 34.5 (17.9 to 54.3) | 30.4 (17.7 to 45.8) | 31.9 (19.1 to 47.1) | 73.8 (65.0 to 81.3) | 74.3 (64.8 to 82.5) | 75.0 (65.6 to 83.0) |
To assess lesion-level PPA \& NPA diagnostic performance of 18F-fluciclovine PET in detecting recurrent brain metastases.
| percentage | Reader 1 - Positive Percent Agreement (PPA) | Reader 2 - Positive Percent Agreement (PPA) | Reader 3 - Positive Percent Agreement (PPA) | Reader 1 - Negative Percent Agreement (NPA) | Reader 2 - Negative Percent Agreement (NPA) | Reader 3 - Negative Percent Agreement (NPA) |
|---|---|---|---|---|---|---|
| Lesion-level Positive Percent Agreement (PPA) and Negative Percent Agreement (NPA) | 18.4 (7.3 to 29.4) | 28.6 (15.8 to 41.4) | 30.6 (17.7 to 43.5) | 84.1 (77.4 to 90.7) | 74.6 (66.6 to 82.7) | 73.2 (65.0 to 81.4) |
To assess lesion-level PPV \& NPV diagnostic performance of 18F-fluciclovine PET in detecting recurrent brain metastases.
| percentage | Reader 1 - Positive Predictive Value (PPV) | Reader 2 - Positive Predictive Value (PPV) | Reader 3 - Positive Predictive Value (PPV) | Reader 1 - Negative Predictive Value (NPV) | Reader 2 - Negative Predictive Value (NPV) | Reader 3 - Negative Predictive Value (NPV) |
|---|---|---|---|---|---|---|
| Lesion-level Positive Predictive Value (PPV) and Negative Predictive Value (NPV) | 29.0 (12.1 to 45.9) | 28.6 (15.2 to 42.0) | 28.8 (15.3 to 42.4) | 74.4 (65.5 to 83.2) | 74.6 (65.4 to 83.9) | 74.8 (65.8 to 83.8) |
Sub-group analyses of subject-level PPA \& NPA of fluciclovine (18F) PET, according to primary tumor type.
| percentage | Reader 1 - Positive Percent Agreement (NPA) | Reader 2 - Positive Percent Agreement (NPA) | Reader 3 - Positive Percent Agreement (NPA) | Reader 1 - Negative Percent Agreement (NPA) | Reader 2 - Negative Percent Agreement (NPA) | Reader 3 - Negative Percent Agreement (NPA) |
|---|---|---|---|---|---|---|
| Melanoma | 50.0 (1.3 to 98.7) | 50.0 (1.3 to 98.7) | 0.0 (0.0 to 84.2) | 83.3 (58.6 to 96.4) | 72.2 (46.5 to 90.3) | 66.7 (41.0 to 86.7) |
| Breast | 10.0 (0.3 to 44.5) | 30.0 (6.7 to 65.3) | 40.0 (12.2 to 73.8) | 78.3 (56.3 to 92.5) | 65.2 (42.7 to 83.6) | 73.9 (51.6 to 89.8) |
| Lung Cancer | 29.2 (12.6 to 51.1) | 39.1 (19.7 to 61.5) | 43.5 (23.2 to 65.5) | 85.4 (72.2 to 93.9) | 69.4 (54.6 to 81.8) | 67.3 (52.5 to 80.1) |
| Non Lung/Breast/Melanoma | 16.7 (0.4 to 64.1) | 16.7 (0.4 to 64.1) | 16.7 (0.4 to 64.1) | 80.0 (56.3 to 94.3) | 80.0 (56.3 to 94.3) | 80.0 (56.3 to 94.3) |
Sub-group analyses of subject-level PPV \& NPV of fluciclovine (18F) PET, according to primary tumor type.
| percentage | Reader 1 - Positive Predictive Value (PPV) | Reader 2 - Positive Predictive Value (PPV) | Reader 3 - Positive Predictive Value (PPV) | Reader 1 - Negative Predictive Value (NPV) | Reader 2 - Negative Predictive Value (NPV) | Reader 3 - Negative Predictive Value (NPV) |
|---|---|---|---|---|---|---|
| Melanoma | 25.0 (0.6 to 80.6) | 16.7 (0.4 to 64.1) | 0.0 (0.0 to 45.9) | 93.8 (69.8 to 99.8) | 92.9 (66.1 to 99.8) | 85.7 (57.2 to 98.2) |
| Breast | 16.7 (0.4 to 64.1) | 27.3 (6.0 to 61.0) | 40.0 (12.2 to 73.8) | 66.7 (46.0 to 83.5) | 68.2 (45.1 to 86.1) | 73.9 (51.6 to 89.8) |
| Lung Cancer | 50.0 (23.0 to 77.0) | 37.5 (18.8 to 59.4) | 38.5 (20.2 to 59.4) | 70.7 (57.3 to 81.9) | 70.8 (55.9 to 83.1) | 71.7 (56.5 to 84.0) |
| Non Lung/Breast/Melanoma | 20.0 (0.5 to 71.6) | 20.0 (0.5 to 71.6) | 20.0 (0.5 to 71.6) | 76.2 (52.8 to 91.8) | 76.2 (52.8 to 91.8) | 76.2 (52.8 to 91.8) |
Sub-group analyses of subject-level PPA \& NPA of fluciclovine (18F) PET, according to concurrent immunotherapy.
| percentage | Reader 1 - Positive Percent Agreement (NPA) | Reader 2 - Positive Percent Agreement (NPA) | Reader 3 - Positive Percent Agreement (NPA) | Reader 1 - Negative Percent Agreement (NPA) | Reader 2 - Negative Percent Agreement (NPA) | Reader 3 - Negative Percent Agreement (NPA) |
|---|---|---|---|---|---|---|
| Received Concurrent Immunotherapy | 0.0 (0.0 to 45.9) | 16.7 (0.4 to 64.1) | 16.7 (0.4 to 64.1) | 100.0 (88.4 to 100.0) | 86.7 (69.3 to 96.2) | 90.0 (73.5 to 97.9) |
| Did Not Receive Concurrent Immunotherapy | 27.8 (14.2 to 45.2) | 37.1 (21.5 to 55.1) | 40.0 (23.9 to 57.9) | 75.9 (65.0 to 84.9) | 65.0 (53.5 to 75.3) | 63.8 (52.2 to 74.2) |
Sub-group analyses of subject-level PPV \& NPV of fluciclovine (18F) PET, according to Concurrent Immunotherapy.
| percentage | Reader 1 - Positive Predictive Value (PPV) | Reader 2 - Positive Predictive Value (PPV) | Reader 3 - Positive Predictive Value (PPV) | Reader 1 - Negative Predictive Value (NPV) | Reader 2 - Negative Predictive Value (NPV) | Reader 3 - Negative Predictive Value (NPV) |
|---|---|---|---|---|---|---|
| Received Concurrent Immunotherapy | — | 20.0 (0.5 to 71.6) | 25.0 (0.6 to 80.6) | 83.3 (67.2 to 93.6) | 83.9 (66.3 to 94.6) | 84.4 (67.2 to 94.7) |
| Did Not Receive Concurrent Immunotherapy | 34.5 (17.9 to 54.3) | 31.7 (18.1 to 48.1) | 32.6 (19.1 to 48.5) | 69.8 (58.9 to 79.2) | 70.3 (58.5 to 80.3) | 70.8 (58.9 to 81.0) |
Number of days taken by the site to establish presence/absence of metastasis by clinical follow-up.
| Days | Subjects Receiving Single IV Administration of 18F Fluciclovine for PET Scan |
|---|---|
| Clinical Usefulness | 112 (77.0 to 142.0) |
Proportion of subjects with additional metastases identified on fluciclovine (18F) PET in addition to SoC brain MRI
| percentage | Subjects Receiving Single IV Administration of 18F Fluciclovine for PET Scan |
|---|---|
| Clinical Usefulness | 1.3 (0.2 to 4.7) |
Proportion of subjects whose prospective diagnostic management plan changed following fluciclovine (18F) PET.
| percentage | Subjects Receiving Single IV Administration of 18F Fluciclovine for PET Scan |
|---|---|
| Clinical Usefulness | 26.5 (19.7 to 34.3) |
Pairwise comparisons of the central reads for the 3 readers (i.e. Reader 1 vs Reader 2, Reader 1 vs Reader 3, and Reader 2 vs Reader 3) at the subject-level. The percentage of results in agreement (i.e. Positive \[1st reader\] / Positive \[2nd reader\], Negative/Negative) is presented.
| percentage | Subjects Receiving Single IV Administration of 18F Fluciclovine for PET Scan |
|---|---|
| Reader 1 vs Reader 2 | 86.1 |
| Reader 1 vs Reader 3 | 84.1 |
| Reader 2 vs Reader 3 | 91.4 |
Pairwise comparisons of the initial read vs re-read of a subset of PET scans for each reader at the subject-level. The percentage of results in agreement (i.e. Positive \[initial read\] / Positive \[re-read\], Negative/Negative) is presented.
| percentage | Subjects Receiving Single IV Administration of 18F Fluciclovine for PET Scan |
|---|---|
| Reader 1 initial read vs re-read | 93.5 |
| Reader 2 initial read vs re-read | 93.5 |
| Reader 3 initial read vs re-read | 100.0 |
Treatment-emergent adverse events (TEAEs) following 18F-fluciclovine injection in the subject population.
| mmHg | Subjects Receiving Single IV Administration of 18F Fluciclovine for PET Scan |
|---|---|
| Systolic Blood Pressure: Pre-IMP Injection | 128.7 ± 17.25 |
| Systolic Blood Pressure: Post PET Scan | 132.4 ± 15.25 |
| Systolic Blood Pressure: Change from Pre to Post | 3.5 ± 12.81 |
| Diastolic Blood Pressure: Pre-IMP Injection | 75.4 ± 10.69 |
| Diastolic Blood Pressure: Post PET Scan | 77.0 ± 10.86 |
| Diastolic Blood Pressure: Change from Pre to Post | 1.5 ± 7.45 |
Treatment-emergent adverse events (TEAEs) following 18F-fluciclovine injection in the subject population.
| beat/min | Subjects Receiving Single IV Administration of 18F Fluciclovine for PET Scan |
|---|---|
| Heart Rate: Pre-IMP Injection | 76.2 ± 13.53 |
| Heart Rate: Post PET Scan | 74.5 ± 12.93 |
| Heart Rate: Change from Pre to Post | -1.7 ± 8.43 |
Treatment-emergent adverse events (TEAEs) following 18F-fluciclovine injection in the subject population.
| breaths/min | Subjects Receiving Single IV Administration of 18F Fluciclovine for PET Scan |
|---|---|
| Respiratory Rate: Pre-IMP Injection | 16.7 ± 2.76 |
| Respiratory Rate: Post PET Scan | 16.5 ± 2.72 |
| Respiratory Rate: Change from Pre to Post | -0.2 ± 1.85 |
Treatment-emergent adverse events (TEAEs) following 18F-fluciclovine injection in the subject population.
| degrees Celsius | Subjects Receiving Single IV Administration of 18F Fluciclovine for PET Scan |
|---|---|
| Body Temperature: Pre-IMP Injection | 36.53 ± 0.419 |
| Body Temperature: Post PET Scan | 36.53 ± 0.455 |
| Body Temperature: Change from Pre to Post | -0.00 ± 0.29 |
Collected over Treatment emerging AEs were captured within 48 hours.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Subjects Receiving Single IV Administration of 18F Fluciclovine for PET Scan | 0/151 (0%) | 2/151 (1.3%) | 15/151 (9.9%) |
| Event | Subjects Receiving Single IV Administration of 18F Fluciclovine for PET Scan |
|---|---|
| SeizureNervous system disorders | 1/151 |
| Metastases to central nervous systemNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/151 |
| Event | Subjects Receiving Single IV Administration of 18F Fluciclovine for PET Scan |
|---|---|
| FatigueGeneral disorders | 4/151 |
| DizzinessNervous system disorders | 2/151 |
| NauseaGastrointestinal disorders | 2/151 |
| Infusion site bruisingGeneral disorders | 1/151 |
| Injection site reactionGeneral disorders | 1/151 |
| HeadacheNervous system disorders | 1/151 |
| ParaesthesiaNervous system disorders | 1/151 |
| SeizureNervous system disorders | 1/151 |
| VomitingGastrointestinal disorders | 1/151 |
| HordeolumInfections and infestations | 1/151 |
| Age, Categorical(Participants) | Subjects Receiving Single IV Administration of 18F Fluciclovine for PET Scan |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 81 |
| >=65 years | 70 |
| Age, Continuous(years) | Subjects Receiving Single IV Administration of 18F Fluciclovine for PET Scan |
|---|---|
| Mean | 61.8 ± 11.22 |
| Sex: Female, Male(Participants) | Subjects Receiving Single IV Administration of 18F Fluciclovine for PET Scan |
|---|---|
| Female | 93 |
| Male | 58 |
| Ethnicity (NIH/OMB)(Participants) | Subjects Receiving Single IV Administration of 18F Fluciclovine for PET Scan |
|---|---|
| Hispanic or Latino | 18 |
| Not Hispanic or Latino | 131 |
| Unknown or Not Reported | 2 |
| Race (NIH/OMB)(Participants) | Subjects Receiving Single IV Administration of 18F Fluciclovine for PET Scan |
|---|---|
| American Indian or Alaska Native | 1 |
| Asian | 5 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 7 |
| White | 134 |
| More than one race | 0 |
| Unknown or Not Reported | 4 |
| Height (cm)(cm) | Subjects Receiving Single IV Administration of 18F Fluciclovine for PET Scan |
|---|---|
| Mean | 168.25 ± 10.002 |
| Weight (kg)(kg) | Subjects Receiving Single IV Administration of 18F Fluciclovine for PET Scan |
|---|---|
| Mean | 78.72 ± 19.665 |
| Body mass index (kg/m2)(Kg/m2) | Subjects Receiving Single IV Administration of 18F Fluciclovine for PET Scan |
|---|---|
| Mean | 27.66 ± 6.314 |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Oct 2020 to primary completion in Jun 2023, 31 months.
Results were first posted in Aug 2025, 2 years 2 months after primary completion.
Of 56 phase 3 interventional studies under Brain Neoplasms, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 48 and three quarters within 269. This study's 31 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fluciclovine F-18